Not all patients need antibiotics before shockwave lithotripsy for urolithiasis
21.10.2025 07:47:57 EEST | HUS | Press release
An international study led by a HUS investigator examined the benefits, adverse effects, and necessity of antibiotics before shockwave lithotripsy in the prevention of infections.

Urolithiasis, or a urinary stone, is a common and painful condition that is often treated with extracorporeal shockwave lithotripsy. In the procedure, precisely targeted sound waves are directed at the stone from outside the body, breaking up the stone into smaller pieces, which are then passed out of the body in the urine. The procedure exposes the patient to urinary tract infections.
Extensive evidence on antibiotic use in shockwave lithotripsy for urolithiasis
An international research group led by Professor Kari Tikkinen from the University of Helsinki, who works as a urologist at HUS, examined the benefits and harms of antibiotic prophylaxis, or the use of antibiotics to prevent infections, in shockwave lithotripsy for urolithiasis.
The study covered over 1700 patients from nine countries, including over 360 HUS patients. The patients were randomized into two groups, one of which received ciprofloxazin and the other placebo before the shockwave lithotripsy procedure. A total of 1.3% of the patients in the antibiotic group and 2.7% of the patients in the placebo group were diagnosed with symptomatic urinary tract infection. Pyelonephritis only occurred in the placebo group with no cases reported in the antibiotic group. Urosepsis was not observed, and no severe adverse effects were reported.
The global threat of antibiotic resistance must be taken into account, and antibiotics should be used with consideration
“One dose of ciprofloxazin can reduce the risk of serious infection, but as the absolute benefit is low, the decision on the use of antibiotic prophylaxis should be made on a case-by-case basis, taking into account the patient’s risk factors, what the patient wants, and the prevention of antibiotic resistance,” Tikkinen says.
The results of the APPEAL trial led by Tikkinen provide a basis for updating international treatment guidelines. Tikkinen points out that healthcare needs to develop better ways of identifying the patients who benefit the most from the use of antibiotic prophylaxis. A dose of antibiotics before a shockwave lithotripsy procedure may prevent rare but severe infections, but it is not needed for most low-risk patients.
Link to the research article: A Multicenter Randomized Controlled Trial of Antimicrobial Prophylaxis to Prevent Urinary Tract Infections after Shockwave Lithotripsy for Urolithiasis: The APPEAL Trial
In a university hospital, research is part of the treatment: we continuously evaluate and develop care based on scientific research evidence and patient experience. At HUS, we conduct close research collaboration with the Faculty of Medicine at the University of Helsinki. We publish approximately 2,400 peer-reviewed research articles) annually, which we highlight in our newsfeed.
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Svår RS-virusinfektion kan öka risken att barnet drabbas av astma i den tidiga barndomen8.9.2026 07:55:55 EEST | Pressmeddelande
En svår RS-virusinfektion i spädbarnsåldern ser ut att öka risken för pipande andning och astma i den tidiga barndomen. I en nyligen publicerad studie identifierades också ett nytt genområde som är förknippat med benägenheten att drabbas av RS-virusinfektion.
Vaikea RSV-infektio voi lisätä lapsen riskiä sairastua astmaan varhaislapsuudessa8.9.2026 07:55:55 EEST | Tiedote
Vauvana sairastettu vakava RSV-infektio näyttää lisäävän hengityksen vinkunan ja astman riskiä varhaislapsuudessa. Vastajulkaistussa tutkimuksessa tunnistettiin myös uusi geenialue, joka liittyy alttiuteen sairastua RSV-infektioon.
A child's severe RSV infection may increase the risk of asthma in early childhood8.9.2026 07:55:55 EEST | Press release
A severe RSV infection in infancy appears to increase the risk of wheezing and asthma in early childhood. A newly published study also identified a novel gene locus associated with susceptibility to RSV infection.
HUS-sammanslutningens styrelse beslutade om ändringar i HUS Fastigheter Ab:s och HUS Säkerhetstjänster Ab:s verksamhet7.9.2026 13:57:44 EEST | Pressmeddelande
HUS-sammanslutningens styrelse behandlade dessutom den utredning som Apottis ägare beställt om de framtida alternativen för kund- och patientdatasystemet.
HUSin yhtymähallitus päätti HUS Kiinteistöt Oy:n ja HUS Turvapalvelut Oy:n toimintojen muutoksista7.9.2026 13:57:44 EEST | Tiedote
HUSin yhtymähallitus käsitteli lisäksi Apotin omistajien tilaamaa selvitystä asiakas- ja potilastietojärjestelmän tulevaisuuden vaihtoehdoista.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom